<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infection</journal-id><journal-id journal-id-type="iso-abbrev">Infection</journal-id><journal-title-group><journal-title>Infection</journal-title></journal-title-group><issn pub-type="ppub">0300-8126</issn><issn pub-type="epub">1439-0973</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23180507</article-id><article-id pub-id-type="pmc">3566391</article-id><article-id pub-id-type="publisher-id">367</article-id><article-id pub-id-type="doi">10.1007/s15010-012-0367-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical and Epidemiological Study</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schaper</surname><given-names>N. C.</given-names></name><address><phone>+31-43-387-7019
</phone><fax>+31-43-387-5006</fax><email>n.schaper@mumc.nl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dryden</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kujath</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Nathwani</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Arvis</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Reimnitz</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Alder</surname><given-names>J.</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Gyssens</surname><given-names>I. C.</given-names></name><xref ref-type="aff" rid="Aff8"/><xref ref-type="aff" rid="Aff9"/><xref ref-type="aff" rid="Aff10"/></contrib><aff id="Aff1"><label/>Department of Internal Medicine, Division of Endocrinology, CARIM and CAPHRI Institute, Maastricht University Medical Center+, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands </aff><aff id="Aff2"><label/>Royal Hampshire County Hospital, Winchester, Hampshire UK </aff><aff id="Aff3"><label/>University Clinic of Luebeck, Ratzeburger Allee 160, Luebeck, Germany </aff><aff id="Aff4"><label/>Infection Unit, Ninewells Hospital and Medical School, Dundee, UK </aff><aff id="Aff5"><label/>Bayer HealthCare, Loos, France </aff><aff id="Aff6"><label/>Bayer Pharma AG, Wuppertal, Germany </aff><aff id="Aff7"><label/>Bayer HealthCare, Montville, NJ USA </aff><aff id="Aff8"><label/>Department of Medicine, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands </aff><aff id="Aff9"><label/>Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands </aff><aff id="Aff10"><label/>Hasselt University, Diepenbeek, Belgium </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2013</year></pub-date><volume>41</volume><issue>1</issue><fpage>175</fpage><lpage>186</lpage><history><date date-type="received"><day>9</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>6</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objective</title><p>The aim was to compare the efficacy and safety of two antibiotic regimens in patients with diabetic foot infections (DFIs).</p></sec><sec><title>Methods</title><p>Data of a subset of patients enrolled in the RELIEF trial with DFIs requiring surgery and antibiotics were evaluated retrospectively. DFI was diagnosed on the basis of the modified Wagner, University of Texas, and PEDIS classification systems. Patients were randomized to receive either intravenous/oral moxifloxacin (MXF, <italic>N</italic>&#x000a0;=&#x000a0;110) 400&#x000a0;mg q.d. or intravenous piperacillin/tazobactam 4.0/0.5&#x000a0;g t.d.s. followed by oral amoxicillin/clavulanate 875/125&#x000a0;mg b.d. (PIP/TAZ&#x02013;AMC, <italic>N</italic>&#x000a0;=&#x000a0;96), for 7&#x02013;21&#x000a0;days until the end of treatment (EOT). The primary endpoint was clinical cure rates in the per-protocol (PP) population at the test-of-cure visit (TOC, 14&#x02013;28&#x000a0;days after EOT).</p></sec><sec><title>Results</title><p>There were no significant differences between the demographic characteristics of PP patients in either treatment group. At TOC, MXF and PIP/TAZ&#x02013;AMC had similar efficacy in both the PP and intent-to-treat (ITT) populations: MXF: 76.4&#x000a0;% versus PIP/TAZ&#x02013;AMC: 78.1&#x000a0;%; 95&#x000a0;% confidence interval (CI) &#x02212;14.5&#x000a0;%, 9.0&#x000a0;% in the PP population; MXF: 69.9&#x000a0;% versus PIP/TAZ&#x02013;AMC: 69.1&#x000a0;%; 95&#x000a0;% CI &#x02212;12.4&#x000a0;%, 12.1&#x000a0;% in the ITT population. The overall bacteriological success rates were similar in both treatment groups (MXF: 71.7&#x000a0;% versus PIP/TAZ&#x02013;AMC: 71.8&#x000a0;%; 95&#x000a0;% CI &#x02212;16.9&#x000a0;%, 10.7&#x000a0;%). A similar proportion of patients (ITT population) experienced any adverse events in both treatment groups (MXF: 30.9&#x000a0;% versus PIP/TAZ&#x02013;AMC: 31.8&#x000a0;%, respectively). Death occurred in three MXF-treated patients and one PIP/TAZ&#x02013;AMC-treated patient; these were unrelated to the study drugs.</p></sec><sec><title>Conclusion</title><p>Moxifloxacin has shown favorable safety and efficacy profiles in DFI patients and could be an alternative antibiotic therapy in the management of DFI. Clinical trial: NCT00402727.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibiotic therapy</kwd><kwd>Diabetic foot infection</kwd><kwd>Fluoroquinolone</kwd><kwd>Moxifloxacin</kwd><kwd>Controlled clinical trial</kwd><kwd>Sequential therapy</kwd><kwd>Diabetic foot ulcer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2013</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Diabetic foot infections (DFIs) are the most common cause of hospitalization in people with diabetes, accounting for more hospital bed days than any other diabetic complication [<xref ref-type="bibr" rid="CR1">1</xref>]. DFIs have a high burden of disease, for both the patient and the health care system. Unless promptly treated, clinical outcomes are poor, leading to impaired wound healing in case of a diabetic foot ulcer, possible amputation of the lower extremity, and significant financial costs [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Diabetic patients with a DFI are around 50 times more likely to be hospitalized and 150 times more likely to undergo lower extremity amputation than diabetic patients without foot infections [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. It has been estimated that around 1 million patients with diabetes undergo limb amputation each year, a surgical procedure that is associated with significant morbidity and mortality, as well as major social, psychological, and financial consequences [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Peripheral arterial disease (PAD) is common in patients with DFI, and is an important predictor of outcome [<xref ref-type="bibr" rid="CR7">7</xref>]. For this reason, the Infectious Diseases Society of America (IDSA) has recommended the inclusion of PAD patients in order to improve the quality of clinical trials evaluating antimicrobial therapy in skin and soft tissue infection. Despite this recommendation, however, few patients with PAD have been included in DFI trials to date [<xref ref-type="bibr" rid="CR8">8</xref>] and outcome data in this population are lacking.</p><p>The most important pathogens causing DFIs are the aerobic Gram-positive cocci (e.g., <italic>Staphylococcus aureus</italic>), Gram-negative aerobes (e.g., <italic>Enterobacteriaceae</italic>), and anaerobic pathogens (e.g., <italic>Bacteroides</italic> spp.) [<xref ref-type="bibr" rid="CR3">3</xref>]. Most mild to moderate infections are caused by Gram-positive bacteria, while more severe or chronic infections are usually polymicrobial [<xref ref-type="bibr" rid="CR3">3</xref>] and almost half can include anaerobes [<xref ref-type="bibr" rid="CR9">9</xref>]. The severity of DFIs has been classified broadly as mild, moderate, or severe. However, a lack of consensus and consistency in defining infection severity makes comparison across published studies complicated. Although various systems have been developed, no single system has found universal acceptance. The most established system of classification of ulceration, the Wagner system [<xref ref-type="bibr" rid="CR10">10</xref>], has been employed for more than 25&#x000a0;years, but does not apply to infection severity, assessing only ulcer depth and the presence of osteomyelitis or gangrene. While the University of Texas diabetic wound classification system has been validated in DFI and includes the presence of infection, as well as ulcer depth and ischemia, infection severity is, again, not assessed [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. At a more recent international consensus conference, a system of classification of diabetic foot ulcers [perfusion, extent/size, depth/tissue loss, infection, and sensation (PEDIS)] was developed that includes all the key elements of severity of infection. The newer system has been adopted by the IDSA and has been validated by Lavery et al. [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>Optimal management of DFIs is multimodal, involving surgical debridement, antibiotic therapy, scrupulous wound care and offloading, glycemic control, and assessment and treatment of underlying vascular disease if lower extremity amputations are to be avoided [<xref ref-type="bibr" rid="CR2">2</xref>]. In patients with deep ulcers, immediate drainage with removal of all the necrotic tissue should be considered and intravenous antibiotics are started after material is obtained for culture. In the absence of adequate microbiological information, the challenge for clinicians is to select an appropriate empirical antibiotic regimen because timely and proper management of diabetic foot infection together with surgery [<xref ref-type="bibr" rid="CR14">14</xref>] is key to prevent further complications. The patient&#x02019;s previous antibiotic exposure, the pathogens most commonly isolated, and local rates of resistance should all be considered.</p><p>Fluoroquinolones, such as moxifloxacin (MXF), offer possible advantages over other classes of antimicrobial agents for the empirical treatment of DFIs, due to their broad spectrum of activity and pharmacodynamic properties [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. MXF, in particular, has an extended spectrum of activity against aerobic and anaerobic pathogens [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] and can be given intravenously (IV) or orally (PO). The switch between the two formulations is simple as they have similar pharmacokinetic properties [<xref ref-type="bibr" rid="CR17">17</xref>], and MXF penetrates well into inflamed subcutaneous tissues [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>]. A previous IV/PO study of MXF versus &#x003b2;-lactam/&#x003b2;-lactamase inhibitor showed MXF to be effective and well tolerated in the treatment of complicated skin and skin structure infections (cSSSIs) [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>The rationale of the RELIEF study was to provide additional data on the efficacy and safety of MXF in four specific cSSSI diagnoses (major abscess, DFI, wound infection, infected ischemic ulcer) [<xref ref-type="bibr" rid="CR22">22</xref>]; the present paper reports on the efficacy and safety of MXF versus a &#x003b2;-lactam/&#x003b2;-lactamase inhibitor combination in the subgroup of patients with DFI. The RELIEF study is unique in that it addresses the limitations of previous studies by stratification at inclusion, according to the severity of cSSSI and baseline surgery. Moreover, in contrast to most earlier DFI studies, patients with PAD were included. The combination of a &#x003b2;-lactam antibiotic and a &#x003b2;-lactamase inhibitor (piperacillin/tazobactam) was chosen as the comparator, as this combination is known to be effective in treating cSSSIs [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design and patients</title><p>The RELIEF study was a prospective, randomized, double-dummy, double-blind, multinational, multicenter study [<xref ref-type="bibr" rid="CR22">22</xref>], involving adult men and women (&#x02265;18&#x000a0;years old) with a diagnosis of complicated bacterial skin and skin structure infection of &#x0003c;21&#x000a0;days duration that required hospitalization and initial parenteral antibiotic treatment for &#x02265;48&#x000a0;h. DFI patients were enrolled between 11th October 2006 and 9th June 2008. Diagnoses were validated by an independent Data Review Committee (DRC). All patients were stratified before randomization according to the severity of illness (risk class I and II, or III and IV) using the Wilson scoring system [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>Patients had to have at least one of the following criteria: involvement of deep soft tissue (e.g., fascia, muscle layer), need for significant surgical intervention (e.g., surgical drainage or drainage procedure guided by imaging and/or debridement), or association with a significant underlying disease that could complicate treatment response (e.g., cancer except basal- or squamous-cell skin cancers, cardiac, hepatic, immunological, renal, respiratory, transplantation, or vascular disease). Amputation of part of the foot could have been performed in patients who had extensive infection and would not have benefited from other surgeries, but patients could only be included if a cSSSI was still present after completion of this surgery. All initial surgeries had to be completed within 48&#x000a0;h after beginning infusion of the antibiotics.</p><p>All diabetic patients had to have a DFI of mild to severe infection intensity (PEDIS grade 2&#x02013;4) during randomization with or without osteomyelitis (patients with osteomyelitis could only be enrolled if the infected bone was removed and if residual infection was still present). In order to facilitate the comparison of this study with other recent studies, all ulcers were also categorized according to the University of Texas classification system [<xref ref-type="bibr" rid="CR11">11</xref>]. As initial (emergency) surgery, including amputation of part of the foot, within 48&#x000a0;h after inclusion was part of the immediate treatment, post-amputation PEDIS infection scores were retrospectively calculated for all patients to confirm that the infection was still requiring antibiotic treatment.</p><p>In all patients, glycemic control was measured by the plasma level of glycated hemoglobin (HbA<sub>1c</sub>) values. To describe the severity of infection, body temperature and levels of inflammatory markers including C-reactive protein (CRP), procalcitonin (PCT), and white blood cell count (WBC), were documented. Furthermore, wound depth and type of wound care undertaken were also registered. The presence of peripheral neuropathy (assessed by both vibration perception and light pressure testing) and PAD [defined as ankle&#x02013;brachial index (ABI) &#x0003c;0.9 and/or foot pulses barely or not palpable] were also recorded.</p><p>Patients who had received therapy with a systemic or topical antimicrobial for &#x0003e;24&#x000a0;h in the previous 7&#x000a0;days were excluded from the study, unless they were considered to be clinical failures (i.e., the patient showed no response or had worsening of clinical signs and symptoms despite treatment for&#x000a0;&#x02265;3&#x000a0;days) and a culture before enrolment showed persistence of a pathogen that was susceptible to the study drugs.</p></sec><sec id="Sec4"><title>Study treatments</title><p>Patients received sequential IV/PO MXF, 400&#x000a0;mg q.d., plus matching placebo or IV piperacillin/tazobactam (PIP/TAZ), 4.0/0.5&#x000a0;g t.d.s., followed by PO amoxicillin/clavulanic acid (AMC) 875/125&#x000a0;mg b.d. They were treated for a minimum of 7 and a maximum of 21&#x000a0;days. The switch from IV to PO drug was at the investigator&#x02019;s discretion, provided the patient was improving on IV therapy, had no fever, that gastrointestinal absorption was adequate, and the patient had received IV study drug for at least 48&#x000a0;h. The total duration of therapy was also at the investigator&#x02019;s discretion.</p></sec><sec id="Sec5"><title>Assessments</title><p>Clinical efficacy was assessed during treatment (days 3&#x02013;5), at the end of treatment (EOT, 7&#x02013;21&#x000a0;days after inclusion), and at the test-of-cure visit (TOC, 14&#x02013;28&#x000a0;days after EOT). The primary efficacy variable was clinical response at TOC as assessed by the independent DRC. Photographs of skin lesions were taken at each assessment and were used by the DRC, together with blinded patient data, to evaluate clinical response to the study drug at TOC. Patients were considered as clinical failures at any visit who had insufficient lessening of the clinical signs and symptoms of infection such that additional or alternative antimicrobial therapy was required (with or without additional surgery). Clinical cures/successes were patients considered to be cured at TOC and who were not considered as failures at EOT. Patients whose outcome was considered as clinical failure at EOT were counted in the total number of clinical failures at TOC. Safety assessment was based on physical examination, vital signs, ECG, adverse events (AEs), and standard laboratory tests throughout the study.</p></sec><sec id="Sec6"><title>Patient populations</title><p>The RELIEF study had a non-inferiority design [<xref ref-type="bibr" rid="CR22">22</xref>] and the current analysis is based on the subpopulation of patients with DFI in the RELIEF study [<xref ref-type="bibr" rid="CR25">25</xref>]. The main analysis population was the per-protocol (PP) population, consisting of all patients who had received the study drug for &#x02265;72&#x000a0;h (in case of clinical failure) or 7 full days (in case of success), had received &#x02265;48&#x000a0;h of IV therapy, had documented compliance of &#x02265;80&#x000a0;% with study medication, had no protocol violations influencing treatment efficacy, and for whom a clinical evaluation at TOC other than &#x02018;indeterminate&#x02019; (subjects in whom a clinical assessment could not be determined as improvement, resolution, or failure) was available. Confirmatory and safety analyses were carried out on the intent-to-treat (ITT) population (all randomized patients who received at least one dose of study drug and had at least one observation after taking study medication).</p><p>Bacteriological evaluations were performed using the microbiologically valid (MBV) population (all PP patients for whom at least one causative organism could be cultured from an appropriate specimen within 48&#x000a0;h before or following randomization and a bacteriological evaluation at TOC other than &#x02018;indeterminate&#x02019; was available). Confirmatory analyses were carried out on the ITT with organisms population, which included all patients in the ITT population for whom at least one causative organism could be cultured from an appropriate specimen within 48&#x000a0;h before or following randomization.</p></sec><sec id="Sec7"><title>Bacteriological assessments</title><p>Bacteriological evaluation was performed at enrolment, during therapy (days 3&#x02013;5), at EOT, and at TOC. Biospecimens were taken by needle aspiration, tissue biopsy, or curettage for culture, identification of bacteria, and for susceptibility testing against a variety of antibiotics, including study drugs. In addition, susceptibility to oxacillin was tested when staphylococci were isolated and extended-spectrum beta-lactamase (ESBL) activity was determined for <italic>Enterobacteriaceae</italic> species. Acceptable culture specimens included skin biopsy, curettage of the wound base after debridement, tissue or bone biopsy, aspiration of purulent secretions, or a leading-edge needle aspiration for subjects with cellulitis. Cultures should not have been obtained using a swab. All cultured organisms underwent genus and species identification at the central microbiology laboratory. In subjects with initial baseline-positive blood cultures, blood cultures were repeated until the result was negative.</p><p>The study microbiologist reviewed all information before un-blinding the patients according to whether bacteria were colonizing in nature, whether they were part of the normal flora, or whether they likely played a pathogenic role based on its nature and quantitative culture results. Criteria indicating infection rather than colonization included growth of the organism from the deep tissue in the setting of inflammation and purulent drainage [<xref ref-type="bibr" rid="CR14">14</xref>] and Gram-stained smear of the wound showing neutrophils and organisms morphologically compatible with those grown in culture.</p></sec><sec id="Sec8"><title>Statistical methods</title><p>Treatment groups were compared using the Mantel&#x02013;Haenszel estimates and 95&#x000a0;% confidence intervals (CIs) for differences in the cure rates at TOC. For the PP analyses of the clinical and bacteriological responses, the treatment comparisons were performed as &#x0201c;success&#x0201d; versus &#x0201c;non-success&#x0201d; (missing or indeterminate outcomes were not allowed in the PP population). For the ITT analyses, a comparison of &#x0201c;success&#x0201d; versus &#x0201c;non-success&#x0201d; was performed; additionally, an analysis of &#x0201c;success&#x0201d; versus &#x0201c;failure&#x0201d; was compared. Statistical analyses were stratified by the severity of illness based on the Wilson scoring system and the presence or absence of a cSSSI-related surgical procedure prior to or scheduled to take place within 48&#x000a0;h of study entry. Non-inferiority of MXF was demonstrated if the lower limit of the 95&#x000a0;% CI was above &#x02212;10&#x000a0;%. As the RELIEF study was not powered to look at subgroups, the 95&#x000a0;% CIs presented here are exploratory in nature. Adverse events were classified according to MedDRA code and their severity and relationship to study drug assessment. Vital signs and laboratory data were analyzed descriptively.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Patient disposition</title><p>A total of 233 patients with a DFI were randomized into the study (ITT population), of whom 206 were valid for the PP analysis (MXF&#x000a0;=&#x000a0;110, PIP/TAZ&#x02013;AMC&#x000a0;=&#x000a0;96). The patient disposition is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. There were no significant differences between the demographic characteristics of PP patients in either treatment group (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), except that there were more men in the PIP/TAZ&#x02013;AMC group and the mean glycosylated hemoglobin (HbA<sub>1c</sub>) levels were higher in the MXF arm. Patients in both study arms were overweight, had elevated CRP and PCT levels, and more than 80&#x000a0;% were febrile. HbA<sub>1c</sub> levels were considerably higher than those observed in the overall RELIEF population (7.0&#x02013;7.4&#x000a0;%) [<xref ref-type="bibr" rid="CR22">22</xref>], but are consistent with other studies in patients with DFI [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. PAD was evident in over 65&#x000a0;% of all patients, out of whom 129 (62.6&#x000a0;%) had barely or non-palpable pulses in both dorsalis pedis and posterior tibialis arteries, and almost half had peripheral neuropathy (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Most infection types (&#x0003e;87&#x000a0;%) were community acquired (CA). At baseline, most patients had moderate to severe DFIs, with a PEDIS infection score of 3 or 4. Initial surgeries (most commonly amputation or extensive debridement) were carried out on 150 patients (MXF: 70.9&#x000a0;% versus PIP/TAZ: 75.0&#x000a0;%). Although the baseline pre-amputation PEDIS infection scores were similar in the two groups of patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), it was observed that, numerically, but not statistically significantly, more patients in the MXF arm had an amputation as initial (&#x0003c;48&#x000a0;h after randomization) surgery (MXF: <italic>n</italic>&#x000a0;=&#x000a0;51, 46.4&#x000a0;% and PIP/TAZ&#x02013;AMC: <italic>n</italic>&#x000a0;=&#x000a0;33, 34.3&#x000a0;%). PEDIS infection scores were calculated post-amputation to assess whether this had introduced a bias. More patients in the MXF arm had a calculated PEDIS score of 3 (<italic>n</italic>&#x000a0;=&#x000a0;29, 56.9&#x000a0;%) than in the PIP/TAZ&#x02013;AMC arm (<italic>n</italic>&#x000a0;=&#x000a0;13, 39.4&#x000a0;%) post-amputation. A similar number of patients in each treatment arm had mild infection, i.e., PEDIS score of 2 (MXF: <italic>n</italic>&#x000a0;=&#x000a0;22, 43.1&#x000a0;% and PIP/TAZ&#x02013;AMC: <italic>n</italic>&#x000a0;=&#x000a0;20, 60.6&#x000a0;%), while none had a severe infection (i.e., PEDIS score of 4) following amputation in either arm. The mean [standard deviation (SD)] duration of combined IV/PO therapy was similar, being 14.5 (4.5) days in the MXF and 14.2 (4.4) days in the PIP/TAZ&#x02013;AMC groups, respectively. There was no significant difference between the two arms regarding the length of either PO or IV treatments. Intravenous infusion lasted for 8.1&#x000a0;&#x000b1;&#x000a0;4.1&#x000a0;days in the MXF group and 7.5&#x000a0;&#x000b1;&#x000a0;3.3&#x000a0;days in the PIP/TAZ&#x02013;AMC group; PO administration of drugs lasted for 8.1&#x000a0;&#x000b1;&#x000a0;3.2&#x000a0;days in the MXF group and 8.4&#x000a0;&#x000b1;&#x000a0;3.1&#x000a0;days in the PIP/TAZ&#x02013;AMC group. The number of patients who received other antibiotics before treatment with study drugs was similarly low in the MXF (8.2&#x000a0;%) and PIP/TAZ&#x02013;AMC (8.3&#x000a0;%) treatment groups, respectively.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Disposition of patients with diabetic foot infection (DFI). <italic>ITT</italic> intent-to-treat, <italic>MBV</italic> microbiologically valid, <italic>MXF</italic> moxifloxacin, <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid, <italic>PP</italic> per-protocol</p></caption><graphic xlink:href="15010_2012_367_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic and disease characteristics of patients at baseline with diabetic foot infection (DFI) in the RELIEF study [per-protocol (PP) population]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">MXF (<italic>N</italic>&#x000a0;=&#x000a0;110)</th><th align="left">PIP/TAZ&#x02013;AMC (<italic>N</italic>&#x000a0;=&#x000a0;96)</th></tr></thead><tbody><tr><td align="left">Sex, male, <italic>n</italic> (%)</td><td char="(" align="char">61 (55.5)</td><td char="(" align="char">69 (71.9)</td></tr><tr><td align="left">Mean age (years) (SD)</td><td char="(" align="char">58.9 (10.2)</td><td char="(" align="char">59.5 (10.1)</td></tr><tr><td align="left">Mean BMI, kg/m<sup>2</sup> (SD)</td><td char="(" align="char">28.9 (5.7)</td><td char="(" align="char">28.6 (4.7)</td></tr><tr><td align="left">Temperature&#x000a0;&#x0003e;38&#x000a0;&#x000b0;C, <italic>n</italic> (%)</td><td char="(" align="char">98 (89.1)</td><td char="(" align="char">79 (82.3)</td></tr><tr><td align="left">Mean WBC, 10<sup>9</sup>/L (SD)</td><td char="(" align="char">10.0 (4.0)</td><td char="(" align="char">9.3 (3.8)</td></tr><tr><td align="left">Mean HbA<sub>1c</sub> (%) (SD)</td><td char="(" align="char">9.7 (2.5)</td><td char="(" align="char">9.0 (2.1)</td></tr><tr><td align="left">Mean CRP, mg/L (SD)</td><td char="(" align="char">8.3 (8.8)</td><td char="(" align="char">8.7 (8.4)</td></tr><tr><td align="left">Mean PCT, ng/ml (SD)</td><td char="(" align="char">0.2 (0.3)</td><td char="(" align="char">0.2 (0.6)</td></tr><tr><td align="left" colspan="3">Peripheral neuropathy, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Vibration perception test&#x02014;negative<sup>c</sup></td><td char="(" align="char">44 (41.5)</td><td char="(" align="char">48 (51.6)</td></tr><tr><td align="left">&#x000a0;Light pressure test (plantar surface of heel)&#x02014;negative<sup>d</sup></td><td char="(" align="char">52 (49.5)</td><td char="(" align="char">44 (47.8)</td></tr><tr><td align="left">Peripheral arterial disease<sup>a</sup>, <italic>n</italic> (%)</td><td char="(" align="char">72 (65.5)</td><td char="(" align="char">68 (70.8)</td></tr><tr><td align="left">&#x000a0;ABI&#x000a0;&#x0003c;0.9</td><td char="(" align="char">46 (41.8)</td><td char="(" align="char">42 (43.8)</td></tr><tr><td align="left">&#x000a0;Absent or barely palpable dorsalis pedis and posterior tibialis pulses</td><td char="(" align="char">66 (60.0)</td><td char="(" align="char">63 (65.6)</td></tr><tr><td align="left" colspan="3">Infection type, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Community acquired</td><td char="(" align="char">96 (87.3)</td><td char="(" align="char">87 (90.6)</td></tr><tr><td align="left">&#x000a0;Hospital acquired</td><td char="(" align="char">14 (12.7)</td><td char="(" align="char">9 (9.4)</td></tr><tr><td align="left">Mean time since occurrence of symptoms (days) (SD)</td><td char="(" align="char">9.5 (5.4)</td><td char="(" align="char">9.2 (5.6)</td></tr><tr><td align="left">Pre-therapy antibiotic use, <italic>n</italic> (%)</td><td char="(" align="char">9 (8.2)</td><td char="(" align="char">8 (8.3)</td></tr><tr><td align="left">Mean lesion area (cm<sup>2</sup>) (SD)</td><td char="(" align="char">46.9 (66.4)</td><td char="(" align="char">35.1 (48.5)</td></tr><tr><td align="left" colspan="3">Deepest tissue layer infected, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Dermis</td><td char="(" align="char">10 (9.1)</td><td char="(" align="char">6 (6.3)</td></tr><tr><td align="left">&#x000a0;Subcutaneous fat</td><td char="(" align="char">12 (10.9)</td><td char="(" align="char">4 (4.2)</td></tr><tr><td align="left">&#x000a0;Fascia, muscle, or deeper</td><td char="(" align="char">88 (80.0)</td><td char="(" align="char">86 (89.6)</td></tr><tr><td align="left" colspan="3">Type of surgery during first 48&#x000a0;h<sup>b</sup>, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;No surgery</td><td char="(" align="char">32 (29.1)</td><td char="(" align="char">24 (25.0)</td></tr><tr><td align="left">&#x000a0;Abscess drainage</td><td char="(" align="char">28 (25.5)</td><td char="(" align="char">31 (32.3)</td></tr><tr><td align="left">&#x000a0;Local debridement</td><td char="(" align="char">21 (19.1)</td><td char="(" align="char">17 (17.7)</td></tr><tr><td align="left">&#x000a0;Extensive debridement</td><td char="(" align="char">32 (29.1)</td><td char="(" align="char">38 (39.6)</td></tr><tr><td align="left">&#x000a0;Primary closure</td><td char="(" align="char">12 (10.9)</td><td char="(" align="char">8 (8.3)</td></tr><tr><td align="left">&#x000a0;Amputation</td><td char="(" align="char">51 (46.4)</td><td char="(" align="char">33 (34.4)</td></tr><tr><td align="left">&#x000a0;Graft surgery</td><td char="(" align="char">0 (&#x02013;)</td><td char="(" align="char">1 (1.0)</td></tr><tr><td align="left">&#x000a0;Removal of infected bone area</td><td char="(" align="char">21 (19.1)</td><td char="(" align="char">19 (19.8)</td></tr><tr><td align="left">&#x000a0;Revascularization</td><td char="(" align="char">1 (0.9)</td><td char="(" align="char">1 (1.0)</td></tr><tr><td align="left">&#x000a0;Necrectomy</td><td char="(" align="char">0 (&#x02013;)</td><td char="(" align="char">1 (1.0)</td></tr><tr><td align="left" colspan="3">University of Texas wound classification<sup>e</sup>, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;Grade 0, Infected</td><td char="(" align="char">0 (&#x02013;)</td><td char="(" align="char">1 (1.1)</td></tr><tr><td align="left">&#x000a0;Grade 0, Ischemic<sup>a</sup></td><td char="(" align="char">1 (0.9)</td><td char="(" align="char">0 (&#x02013;)</td></tr><tr><td align="left">&#x000a0;Grade I, Infected</td><td char="(" align="char">4 (3.7)</td><td char="(" align="char">1 (1.1)</td></tr><tr><td align="left">&#x000a0;Grade I, Ischemic<sup>a</sup></td><td char="(" align="char">11 (10.3)</td><td char="(" align="char">8 (8.5)</td></tr><tr><td align="left">&#x000a0;Grade II, Infected</td><td char="(" align="char">16 (15.0)</td><td char="(" align="char">14 (14.9)</td></tr><tr><td align="left">&#x000a0;Grade II, Ischemic<sup>a</sup></td><td char="(" align="char">45 (42.1)</td><td char="(" align="char">43 (45.7)</td></tr><tr><td align="left">&#x000a0;Grade III, Infected</td><td char="(" align="char">9 (8.4)</td><td char="(" align="char">2 (2.1)</td></tr><tr><td align="left">&#x000a0;Grade III, Ischemic<sup>a</sup></td><td char="(" align="char">21 (19.6)</td><td char="(" align="char">25 (26.6)</td></tr><tr><td align="left">Wilson score, mean (SD)</td><td char="(" align="char">100.6 (21.9)</td><td char="(" align="char">103.5 (22.5)</td></tr><tr><td align="left">&#x000a0;Risk class I, <italic>n</italic> (%)</td><td char="(" align="char">5 (4.5)</td><td char="(" align="char">4 (4.2)</td></tr><tr><td align="left">&#x000a0;Risk class II, <italic>n</italic> (%)</td><td char="(" align="char">20 (18.2)</td><td char="(" align="char">8 (8.3)</td></tr><tr><td align="left">&#x000a0;Risk class III, <italic>n</italic> (%)</td><td char="(" align="char">34 (30.9)</td><td char="(" align="char">33 (34.4)</td></tr><tr><td align="left">&#x000a0;Risk class IV, <italic>n</italic> (%)</td><td char="(" align="char">51 (46.4)</td><td char="(" align="char">51 (53.1)</td></tr><tr><td align="left" colspan="3">Baseline PEDIS infection score classification of all patients<sup>e</sup>, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;2 (Mild)</td><td char="(" align="char">14 (13.1)</td><td char="(" align="char">8 (8.5)</td></tr><tr><td align="left">&#x000a0;3 (Moderate)</td><td char="(" align="char">87 (81.3)</td><td char="(" align="char">81 (86.2)</td></tr><tr><td align="left">&#x000a0;4 (Severe)</td><td char="(" align="char">6 (5.6)</td><td char="(" align="char">5 (5.3)</td></tr><tr><td align="left" colspan="3">Baseline PEDIS infection score classification before amputation<sup>f</sup>, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;2 (Mild)</td><td char="(" align="char">1 (2.0)</td><td char="(" align="char">0 (0.0)</td></tr><tr><td align="left">&#x000a0;3 (Moderate)</td><td char="(" align="char">47 (92.2)</td><td char="(" align="char">31 (93.9)</td></tr><tr><td align="left">&#x000a0;4 (Severe)</td><td char="(" align="char">3 (5.9)</td><td char="(" align="char">2 (6.1)</td></tr></tbody></table><table-wrap-foot><p><italic>ABI</italic> ankle&#x02013;brachial index; <italic>BMI</italic> body mass index; <italic>CRP</italic> C-reactive protein; <italic>HbA</italic><sub><italic>1c</italic></sub> glycosylated hemoglobin; <italic>MXF</italic> moxifloxacin; <italic>PCT</italic> procalcitonin, <italic>PEDIS</italic> perfusion, extent/size, depth/tissue loss, infection, and sensation; <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid; <italic>SD</italic> standard deviation; <italic>WBC</italic> white blood cell count</p><p><sup>a</sup>Defined as ABI&#x000a0;&#x0003c;0.9 and/or foot pulses barely or not palpable; foot pulses as barely or not palpable were examined in the dorsalis pedis and posterior tibialis arteries</p><p><sup>b</sup>Patients could have &#x02265;1 surgical procedure</p><p><sup>c</sup><italic>n</italic>&#x000a0;=&#x000a0;106 MXF, <italic>n</italic>&#x000a0;=&#x000a0;93 PIP/TAZ&#x02013;AMC</p><p><sup>d</sup><italic>n</italic>&#x000a0;=&#x000a0;105 MXF, <italic>n</italic>&#x000a0;=&#x000a0;92 PIP/TAZ&#x02013;AMC</p><p><sup>e</sup><italic>n</italic>&#x000a0;=&#x000a0;107 MXF, <italic>n</italic>&#x000a0;=&#x000a0;94 PIP/TAZ&#x02013;AMC</p><p><sup>f</sup>Patients (<italic>n</italic>&#x000a0;=&#x000a0;51 MXF, <italic>n</italic>&#x000a0;=&#x000a0;33 PIP/TAZ&#x02013;AMC) exclusively with amputation as initial surgery (either prior to enrolment or within 48&#x000a0;h after the start of study medication)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Baseline bacteriology</title><p>Particular attention was paid as to whether the organisms isolated represented colonizers or pathogens. The presented data in this paper refer to pathogenic bacteria. A total of 92 MXF-treated and 85 PIP/TAZ&#x02013;AMC-treated MBV patients had 347 pathogenic organisms isolated at baseline (MXF: 177, PIP/TAZ&#x02013;AMC: 170), with similar microbiological profiles seen across the two treatment groups. The most commonly isolated organisms as a percentage of all organisms isolated were: methicillin-susceptible <italic>Staphylococcus aureus</italic> (MSSA) (MXF: 53, 29.9&#x000a0;%; PIP/TAZ&#x02013;AMC: 57, 33.5&#x000a0;%), <italic>Enterococcus faecalis</italic> (MXF: 30, 16.9&#x000a0;%; PIP/TAZ&#x02013;AMC: 29, 17.1&#x000a0;%), methicillin-resistant <italic>S. aureus</italic> (MRSA) (MXF: 11, 6.2&#x000a0;%; PIP/TAZ&#x02013;AMC: 12, 7.1&#x000a0;%), non-ESBL-producing <italic>Escherichia coli</italic> (MXF: 8, 4.5&#x000a0;%; PIP/TAZ&#x02013;AMC: 11, 6.5&#x000a0;%), <italic>Bacteroides fragilis</italic> (MXF: 3, 1.7&#x000a0;%; PIP/TAZ&#x02013;AMC: 4, 2.4&#x000a0;%), <italic>Streptococcus pyogenes</italic> (MXF: 3, 1.7&#x000a0;%; PIP/TAZ&#x02013;AMC: 2, 1.2&#x000a0;%), and ESBL-producing <italic>E. coli</italic> (MXF: 1, 0.6&#x000a0;%; PIP/TAZ&#x02013;AMC: 1, 0.6&#x000a0;%). Polymicrobial infections were common, occurring in more than half of all patients (MXF: 60.9&#x000a0;%; PIP/TAZ&#x02013;AMC: 62.3&#x000a0;%).</p></sec><sec id="Sec12"><title>Clinical efficacy</title><p>Clinical cure rates were similar between treatment groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). At TOC, MXF and PIP/TAZ&#x02013;AMC had similar efficacy in both the PP and ITT populations (MXF: 76.4&#x000a0;% versus PIP/TAZ&#x02013;AMC: 78.1&#x000a0;%; 95&#x000a0;% CI &#x02212;14.5&#x000a0;%, 9.0&#x000a0;% in the PP population; MXF: 69.9&#x000a0;% versus PIP/TAZ&#x02013;AMC: 69.1&#x000a0;%; 95&#x000a0;% CI &#x02212;12.4&#x000a0;%, 12.1&#x000a0;% in the ITT population). Similar results were seen in patients of the MBV population (MXF: 69/92, 75.0&#x000a0;% versus PIP/TAZ&#x02013;AMC: 64/85, 75.3&#x000a0;%; 95&#x000a0;% CI &#x02212;15.8&#x000a0;%, 10.6&#x000a0;%) and of the ITT with organisms population (MXF: 71/102, 69.6&#x000a0;% versus PIP/TAZ&#x02013;AMC: 65/96, 67.7&#x000a0;%; 95&#x000a0;% CI &#x02212;13.0&#x000a0;%, 14.1&#x000a0;%). Good clinical efficacy was seen across the range of infection severities, as measured by the University of Texas wound classification, baseline PEDIS infection scores, or the Wilson classification system (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Clinical cure at the test-of-cure visit (TOC) in the per-protocol (PP) and intent-to-treat (ITT) patient populations. <italic>CI</italic> confidence interval, <italic>ITT</italic> intent-to-treat, <italic>MXF</italic> moxifloxacin, <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid, <italic>PP</italic> per-protocol</p></caption><graphic xlink:href="15010_2012_367_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Clinical success by disease severity scoring system (per-protocol population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">MXF<sup>b</sup>, <italic>n</italic>/<italic>N</italic> (%)</th><th align="left">PIP/TAZ&#x02013;AMC<sup>b</sup>, <italic>n</italic>/<italic>N</italic> (%)</th></tr></thead><tbody><tr><td align="left" colspan="3">Texas wound classification</td></tr><tr><td align="left">Grade 0</td><td char="(" align="char">0/1 (0)</td><td char="(" align="char">1/1 (100)</td></tr><tr><td align="left">&#x000a0;Infected</td><td char="(" align="char"/><td char="(" align="char">1/1 (100)</td></tr><tr><td align="left">&#x000a0;Ischemic<sup>a</sup></td><td char="(" align="char">0/1 (0)</td><td char="(" align="char"/></tr><tr><td align="left">Grade I</td><td char="(" align="char">11/15 (73.3)</td><td char="(" align="char">7/9 (77.8)</td></tr><tr><td align="left">&#x000a0;Infected</td><td char="(" align="char">3/4 (75.0)</td><td char="(" align="char">1/1 (100)</td></tr><tr><td align="left">&#x000a0;Ischemic<sup>a</sup></td><td char="(" align="char">8/11 (72.7)</td><td char="(" align="char">6/8 (75.0)</td></tr><tr><td align="left">Grade II</td><td char="(" align="char">45/61 (73.8)</td><td char="(" align="char">47/57 (82.5)</td></tr><tr><td align="left">&#x000a0;Infected</td><td char="(" align="char">12/16 (75.0)</td><td char="(" align="char">14/14 (100)</td></tr><tr><td align="left">&#x000a0;Ischemic<sup>a</sup></td><td char="(" align="char">33/45 (73.3)</td><td char="(" align="char">33/43 (76.7)</td></tr><tr><td align="left">Grade III</td><td char="(" align="char">25/30 (83.3)</td><td char="(" align="char">18/27 (66.7)</td></tr><tr><td align="left">&#x000a0;Infected</td><td char="(" align="char">9/9 (100)</td><td char="(" align="char">2/2 (100)</td></tr><tr><td align="left">&#x000a0;Ischemic<sup>a</sup></td><td char="(" align="char">16/21 (76.2)</td><td char="(" align="char">16/25 (64.0)</td></tr><tr><td align="left" colspan="3">PEDIS infection score classification prior to any surgery</td></tr><tr><td align="left">&#x000a0;2 (Mild)</td><td char="(" align="char">12/14 (85.7)</td><td char="(" align="char">6/8 (75.0)</td></tr><tr><td align="left">&#x000a0;3 (Moderate)</td><td char="(" align="char">66/87 (75.9)</td><td char="(" align="char">64/81 (79.0)</td></tr><tr><td align="left">&#x000a0;4 (Severe)</td><td char="(" align="char">3/6 (50.0)</td><td char="(" align="char">3/5 (60.0)</td></tr><tr><td align="left" colspan="3">Wilson classification</td></tr><tr><td align="left">&#x000a0;Risk class I</td><td char="(" align="char">4/5 (80.0)</td><td char="(" align="char">4/4 (100)</td></tr><tr><td align="left">&#x000a0;Risk class II</td><td char="(" align="char">15/20 (75.0)</td><td char="(" align="char">7/8 (87.5)</td></tr><tr><td align="left">&#x000a0;Risk class III</td><td char="(" align="char">30/34 (88.2)</td><td char="(" align="char">28/33 (84.8)</td></tr><tr><td align="left">&#x000a0;Risk class IV</td><td char="(" align="char">35/51 (68.6)</td><td char="(" align="char">36/51 (70.6)</td></tr></tbody></table><table-wrap-foot><p><italic>MXF</italic> moxifloxacin, <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid</p><p><italic>n</italic>/<italic>N</italic>&#x000a0;=&#x000a0;number of patients with clinical cure/total number of patients</p><p><italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05 in all cases, Cochran&#x02013;Mantel&#x02013;Haenszel test</p><p><sup>a</sup>Defined as ABI&#x000a0;&#x0003c;0.9 and/or foot pulses barely or not palpable</p><p><sup>b</sup>MXF: <italic>N</italic>&#x000a0;=&#x000a0;107; PIP/TAZ&#x02013;AMC: <italic>N</italic>&#x000a0;=&#x000a0;94</p></table-wrap-foot></table-wrap></p><p>Additional surgeries &#x0003e;48&#x000a0;h after the start of therapy (including amputation) were carried out on 20.9&#x000a0;% of MXF-treated and 25.0&#x000a0;% of PIP/TAZ&#x02013;AMC-treated patients (PP populations). Of these, fewer MXF versus PIP/TAZ&#x02013;AMC patients required amputation (8.2 versus 16.7&#x000a0;%, respectively), but these differences were not statistically different.</p></sec><sec id="Sec13"><title>Bacteriological response</title><p>The susceptibility to the administered antibiotics of the most common bacteria isolated in our DFI patients is shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The most prevalent causative species (MSSA) was susceptible to both antibiotics used, while the second most frequently isolated species (<italic>E. faecalis</italic>) was resistant to both MXF and PIP/TAZ in a small percentage of cases [i.e., 5 out of 34 isolates (14.7&#x000a0;%) and 5 out of 33 isolates (15.1&#x000a0;%) in both treatment groups, respectively].<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Pre-therapy minimum inhibitory concentrations of study drugs against common pathogens (ITT with pathogens population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2"><italic>N</italic></th><th align="left" colspan="3">MXF (mg/L)</th><th align="left" colspan="3">PIP/TAZ (mg/L)</th><th align="left" colspan="3">AMC (mg/L)</th></tr><tr><th align="left">MIC<sub>50</sub></th><th align="left">MIC<sub>90</sub></th><th align="left">Range</th><th align="left">MIC<sub>50</sub></th><th align="left">MIC<sub>90</sub></th><th align="left">Range</th><th align="left">MIC<sub>50</sub></th><th align="left">MIC<sub>90</sub></th><th align="left">Range</th></tr></thead><tbody><tr><td align="left" colspan="11"><italic>Staphylococcus aureus</italic></td></tr><tr><td align="left">Methicillin-susceptible</td><td char="." align="char">125</td><td align="left">0.03</td><td char="." align="char">0.06</td><td align="left">&#x02264;0.015&#x02013;4.0</td><td char="." align="char">1.0</td><td align="left">2.0</td><td align="left">0.5&#x02013;2.0</td><td align="left">0.50</td><td align="left">1.0</td><td align="left">&#x02264;0.06&#x02013;2.0</td></tr><tr><td align="left">Methicillin-resistant</td><td char="." align="char">27</td><td align="left">2.0</td><td char="." align="char">8.0</td><td align="left">0.12&#x02013;8.0</td><td char="." align="char">16.0</td><td align="left">&#x0003e;128</td><td align="left">4.0 to &#x0003e;128</td><td align="left">8.0</td><td align="left">&#x0003e;32.0</td><td align="left">2.0 to &#x0003e;32.0</td></tr><tr><td align="left"><italic>Enterococcus faecalis</italic></td><td char="." align="char">67</td><td align="left">0.25</td><td char="." align="char">16.0</td><td align="left">0.12&#x02013;16.0</td><td char="." align="char">4.0</td><td align="left">8.0</td><td align="left">2.0 to &#x0003e;128</td><td align="left">1.0</td><td align="left">1.0</td><td align="left">0.25&#x02013;32.0</td></tr><tr><td align="left" colspan="11"><italic>Escherichia coli</italic></td></tr><tr><td align="left">Non-ESBL-producing</td><td char="." align="char">20</td><td align="left">0.03</td><td char="." align="char">32.0</td><td align="left">0.03 to &#x0003e;32.0</td><td char="." align="char">2.0</td><td align="left">2.0</td><td align="left">0.5&#x02013;2.0</td><td align="left">4.0</td><td align="left">8.0</td><td align="left">2.0&#x02013;8.0</td></tr><tr><td align="left"><italic>Bacteroides fragilis</italic></td><td char="." align="char">10</td><td align="left">0.5</td><td char="." align="char">2.0</td><td align="left">0.5&#x02013;4.0</td><td char="." align="char">0.25</td><td align="left">0.5</td><td align="left">0.12&#x02013;1.0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p><italic>ESBL</italic> extended-spectrum beta-lactamase, <italic>N</italic> total number of isolates, <italic>ITT</italic> intent-to-treat, <italic>MXF</italic> moxifloxacin, <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid; <italic>Streptococcus pyogenes</italic> (<italic>n</italic>&#x000a0;=&#x000a0;6): for MXF: MIC<sub>50</sub> 0.12, MIC<sub>90</sub> 0.25, range 0.12&#x02013;0.25; for PIP/TAZ: MIC<sub>50</sub> &#x02264;0.25, MIC<sub>90</sub> &#x02264;0.25, range &#x02264;0.25 to &#x02264;0.25; for AMC: MIC<sub>50</sub> &#x02264;0.06, MIC<sub>90</sub> &#x02264;0.06, range &#x02264;0.06 to &#x02264;0.06; <italic>Escherichia coli</italic> ESBL-producing (<italic>n</italic>&#x000a0;=&#x000a0;3): for MXF: MIC<sub>90</sub> &#x02265;32.0; for PIP/TAZ: MIC<sub>90</sub>&#x000a0;=&#x000a0;16.0; for AMC: MIC<sub>90</sub>&#x000a0;=&#x000a0;16.0</p></table-wrap-foot></table-wrap></p><p>Overall the proportion of patients with bacteriological success in the MBV (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) population were similar across treatment arms (MXF: 71.7&#x000a0;% versus PIP/TAZ&#x02013;AMC: 71.8&#x000a0;%) and no difference was found between treatment groups (95&#x000a0;% CI &#x02212;16.9&#x000a0;%, 10.7&#x000a0;%). Data from patients in the ITT with organisms population support that MXF was as effective as PIP/TAZ&#x02013;AMC (95&#x000a0;% CI &#x02212;13.0&#x000a0;%, 14.6&#x000a0;%). A similar bacteriological outcome was observed for the most commonly isolated pathogens between the two treatment arms (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Eradication of MSSA was numerically higher with MXF treatment. In the small number of patients who had MRSA, the proportion achieving eradication for this species was similar. The proportion of patients achieving bacteriological eradication of monomicrobial (MXF: 25/36, 69.4&#x000a0;% versus PIP/TAZ&#x02013;AMC: 23/32, 71.9&#x000a0;%) or polymicrobial infections (MXF: 43/56, 76.8&#x000a0;% versus PIP/TAZ&#x02013;AMC: 38/53, 71.7&#x000a0;%) were relatively similar between treatment groups. The lowest percentages (&#x0003c;70&#x000a0;%) of bacteriological success among the most frequent organisms were observed for infections with <italic>E. faecalis</italic> for both treatment groups; this species was mainly isolated from polymicrobial infections.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Bacteriological success overall and by key organisms</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="3">Bacteriological success by patients</th></tr><tr><th align="left"/><th align="left">MXF, <italic>n</italic>/<italic>N</italic> (%)</th><th align="left">PIP/TAZ&#x02013;AMC, <italic>n</italic>/<italic>N</italic> (%)</th></tr></thead><tbody><tr><td align="left">MBV</td><td char="(" align="char">66/92 (71.7)</td><td char="(" align="char">61/85 (71.8)</td></tr><tr><td align="left">ITT with organisms</td><td char="(" align="char">69/102 (67.6)</td><td char="(" align="char">62/96 (64.6)</td></tr><tr><td align="left" colspan="3">Bacteriological success by key organism (MBV population)<sup>a</sup></td></tr><tr><td align="left" colspan="3"><italic>Staphylococcus aureus</italic></td></tr><tr><td align="left">Methicillin-susceptible</td><td char="(" align="char">43/53 (81.1)</td><td char="(" align="char">39/57 (68.4)</td></tr><tr><td align="left">Methicillin-resistant</td><td char="(" align="char">8/11 (72.7)</td><td char="(" align="char">10/12 (83.3)</td></tr><tr><td align="left"><italic>Streptococcus pyogenes</italic></td><td char="(" align="char">3/3 (100)</td><td char="(" align="char">2/2 (100)</td></tr><tr><td align="left"><italic>Enterococcus faecalis</italic></td><td char="(" align="char">19/30 (63.3)</td><td char="(" align="char">20/29 (69.0)</td></tr><tr><td align="left" colspan="3"><italic>Escherichia coli</italic></td></tr><tr><td align="left">ESBL-producing</td><td char="(" align="char">1/1 (100)</td><td char="(" align="char">1/1 (100)</td></tr><tr><td align="left">Non-ESBL-producing</td><td char="(" align="char">6/8 (75.0)</td><td char="(" align="char">8/11 (72.7)</td></tr><tr><td align="left"><italic>Bacteroides fragilis</italic></td><td char="(" align="char">3/3 (100)</td><td char="(" align="char">3/4 (75.0)</td></tr></tbody></table><table-wrap-foot><p><italic>ITT</italic> intent-to-treat, <italic>MBV</italic> microbiologically valid, <italic>ESBL</italic> extended-spectrum beta-lactamase, <italic>MXF</italic> moxifloxacin, <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid</p><p><sup>a</sup><italic>n</italic>/<italic>N</italic>&#x000a0;=&#x000a0;number organisms with eradication or presumed eradication/total number of organisms isolated</p></table-wrap-foot></table-wrap></p><p>The emergence of resistant bacteria with moxifloxacin treatment was rare while on therapy or post-therapy in both treatment groups, and it was only seen for one <italic>Klebsiella pneumoniae</italic> (non-ESBL) isolate (pre-therapy: MIC<sub>90</sub>&#x000a0;=&#x000a0;0.12&#x000a0;mg/L, during therapy: MIC<sub>90</sub>&#x000a0;=&#x000a0;8.0&#x000a0;mg/L, EOT: MIC<sub>90</sub>&#x000a0;=&#x000a0;8.0&#x000a0;mg/L) and one <italic>Acinetobacter baumannii</italic> isolate (pre-therapy: MIC<sub>90</sub>&#x000a0;=&#x000a0;1.0&#x000a0;mg/L, during therapy: MIC<sub>90</sub>&#x000a0;=&#x000a0;2.0&#x000a0;mg/L, EOT: MIC<sub>90</sub>&#x000a0;=&#x000a0;8.0&#x000a0;mg/L).</p></sec><sec id="Sec14"><title>Safety</title><p>The total numbers of patients with a DFI experiencing any adverse event were comparable between the MXF [38 (30.9&#x000a0;%)] and PIP/TAZ&#x02013;AMC [35 (31.8&#x000a0;%)] groups (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). Only two moxifloxacin-treated patients (1.6&#x000a0;%) experienced drug-related serious adverse events (SADR) and none (0&#x000a0;%) in the other treatment arm; those two reported SADR cases in the MXF arm occurred as asymptomatic prolongation of ECG QT interval with permanent discontinuation of the study drug. Death occurred in three MXF (2.4&#x000a0;%) and one PIP/TAZ&#x02013;AMC (0.9&#x000a0;%) treatment patients and none of these was reported to be drug-related (three MXF patients died due to respiratory failure, pulmonary embolism, and cardiovascular and renal failure, and one PIP/TAZ&#x02013;AMC patient died due to arterial thromboembolism).<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Overview of treatment-emergent adverse events in patients and the most frequent adverse events (&#x02265;3 in either treatment group, ITT/safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Event</th><th align="left">MXF (<italic>N</italic>&#x000a0;=&#x000a0;123), <italic>n</italic> (%)</th><th align="left">PIP/TAZ&#x02013;AMC (<italic>N</italic>&#x000a0;=&#x000a0;110), <italic>n</italic> (%)</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Adverse event (AE)</td><td char="(" align="char">38 (30.9)</td><td char="(" align="char">35 (31.8)</td><td align="left">0.89</td></tr><tr><td align="left">&#x000a0;Diarrhea</td><td char="(" align="char">1 (0.8)</td><td char="(" align="char">4 (3.6)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Gangrene</td><td char="(" align="char">2 (1.6)</td><td char="(" align="char">3 (2.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Nausea</td><td char="(" align="char">2 (1.6)</td><td char="(" align="char">3 (2.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Blood creatinine increased</td><td char="(" align="char">3 (2.4)</td><td char="(" align="char">1 (0.9)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Creatinine renal clearance decreased</td><td char="(" align="char">3 (2.4)</td><td char="(" align="char">1 (0.9)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Electrocardiogram QT prolonged</td><td char="(" align="char">3 (2.4)</td><td char="(" align="char">1 (0.9)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Pyrexia</td><td char="(" align="char">1 (0.8)</td><td char="(" align="char">3 (2.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Abscess limb</td><td char="(" align="char">0 (&#x02013;)</td><td char="(" align="char">3 (2.7)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Insomnia</td><td char="(" align="char">3 (2.4)</td><td char="(" align="char">2 (1.8)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Hypertension</td><td char="(" align="char">5 (4.1)</td><td char="(" align="char">1 (0.9)</td><td align="left"/></tr><tr><td align="left">&#x000a0;&#x000a0;Drug-related AE</td><td char="(" align="char">12 (9.8)</td><td char="(" align="char">11 (10.0)</td><td align="left">1.00</td></tr><tr><td align="left">&#x000a0;&#x000a0;Premature discontinuation due to AE</td><td char="(" align="char">5 (4.1)</td><td char="(" align="char">2 (1.8)</td><td align="left">0.45</td></tr><tr><td align="left">Serious AE</td><td char="(" align="char">13 (10.6)</td><td char="(" align="char">10 (9.1)</td><td align="left">0.83</td></tr><tr><td align="left">&#x000a0;Drug-related SAE</td><td char="(" align="char">2 (1.6)</td><td char="(" align="char">0 (0.0)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Premature discontinuation due to drug-related SAE</td><td char="(" align="char">2 (1.6)</td><td char="(" align="char">0 (0.0)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Deaths</td><td char="(" align="char">3 (2.4)</td><td char="(" align="char">1 (0.9)</td><td align="left">0.62</td></tr></tbody></table><table-wrap-foot><p><italic>AE</italic> adverse event, <italic>SAE</italic> serious adverse event, <italic>ITT</italic> intent-to-treat, <italic>MXF</italic> moxifloxacin, <italic>PIP/TAZ&#x02013;AMC</italic> piperacillin/tazobactam&#x02013;amoxicillin/clavulanic acid</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>MXF IV/PO therapy had similar efficacy compared with PIP/TAZ&#x02013;AMC therapy in patients with moderate to severe DFI in a randomized double-blind trial in which patients were prospectively stratified according to the severity of illness and the need for surgery. Previous DFI trials have failed to document important disease parameters and baseline data such as infection severity and wound classification at study entry, making comparison between studies difficult [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. In contrast, the patients in the present study were well characterized, with a range of important baseline characteristics such as body mass index (BMI), degree of glycemic control, levels of inflammatory markers, presence of limb ischemia, wound type and care, and severity of infection being documented. These parameters have been highlighted in a recent review as key parameters to be included in order to improve the quality of future DFI studies [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Patients in the current study were recruited across a range of infection severities, though most of the DFI patients (&#x0003e;80&#x000a0;%) had moderate to severe infections with a PEDIS infection score of 3 and could be considered as difficult-to-treat patients. As expected, a relatively high number of patients required initial surgery, one of the cornerstones in the treatment of severe foot infections, which could have introduced bias. However, the post-initial surgery PEDIS infection scores did not differ between both treatment arms.</p><p>An additional strength of the current study is that the majority (&#x0003e;65&#x000a0;%) of the RELIEF study patients with a DFI had also signs of PAD. PAD is present in around half of all patients with foot ulcers [<xref ref-type="bibr" rid="CR7">7</xref>], yet, a number of earlier clinical trials of antibiotics in DFIs enrolled few PAD patients [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>] or excluded those with critical limb ischemia [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] or PAD requiring revascularization [<xref ref-type="bibr" rid="CR23">23</xref>]. In the large-scale Eurodiale study, the outcome of DFIs in patients without PAD was relatively good, but particularly poor results were obtained in DFI patients with PAD [<xref ref-type="bibr" rid="CR35">35</xref>]. As previously demonstrated, treatment with IV or PO moxifloxacin in DFI patients achieves a concentration well above MIC<sub>90</sub> for most pathogenic bacteria in peri-necrotic limb tissue [<xref ref-type="bibr" rid="CR19">19</xref>], suggesting that PK/PD properties of moxifloxacin are able to overcome the potential lack of perfusion due to PAD.</p><p>Whether the antibiotic agent reaches its site-of-action with sufficiently high levels is a critical point in DFI patients with PAD and limb ischemia, and has been investigated in previous studies [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. For example, Zammit et al. [<xref ref-type="bibr" rid="CR38">38</xref>] have investigated the impact of increasing severity of PAD on the tissue concentration of gentamicin in patients with ischemic ulcers. These authors have found a strong inverse correlation between PAD severity and local limb tissue concentration of the antibiotic drug, suggesting that local blood flow regulation is an important determinant of drug efficacy. Similarly, the penetration of ceftazidime into bone and soft tissues was found to be correlated in another study with the degree of tissue perfusion in both diabetic and non-diabetic patients [<xref ref-type="bibr" rid="CR34">34</xref>]. Moreover, diminished and impaired microcirculation could well be a complicating factor for why DFI patients require antibiotic treatment for a long period of time (i.e., the mean duration of therapy in the current study was &#x0003e;14&#x000a0;days). There were 17 patients in nine different study centers who had critical limb ischemia with an ABI&#x000a0;&#x0003c;0.5 (12 MXF patients and five PIP/TAZ&#x02013;AMC patients). Only one of these patients underwent a revascularization procedure during the study period, suggesting that the treatment of PAD was in our patients suboptimal and that better results may have been obtained with a more aggressive approach.</p><p>The burden of disease due to the DFI was high in our study, with 53&#x000a0;% of all patients undergoing an amputation either as initial treatment or during the course of the treatment. Patients in this study had a severe condition at baseline due to poor glycemic control (mean HbA<sub>1c</sub> of nearly 10&#x000a0;%) and elevated inflammatory markers (WBC, CRP, and PCT). Earlier diagnosis and treatment of a diabetic foot ulcer with better glycemic control or earlier recognition of the presence of infection in these patients with prompt institution of appropriate multidisciplinary management might have prevented the development of a more severe infection in many of our patients.</p><p>In the current study, both MXF and PIP/TAZ&#x02013;AMC had relatively high clinical efficacy rates with respect to clinical cure at TOC across all patient populations and sequential IV/PO MXF was as effective as IV/PO PIP/TAZ&#x02013;AMC, thus, confirming the results of previous studies [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p>To date, no single agent has been found to be the most effective for the treatment of moderate to severe DFI and, usually, therapy is selected on an empirical basis, either a broad-spectrum agent or a combination of agents that provide a broad spectrum [<xref ref-type="bibr" rid="CR21">21</xref>]. The current results with MXF are particularly promising, as not only does MXF offer a broad spectrum of activity, permitting the agent to be used in monotherapy, but its IV and oral formulations are similar in their pharmacokinetic properties, so that the switch between IV and PO is simple.</p><p>The range of baseline pathogens isolated and infection types was as anticipated, with the most commonly occurring pathogen being <italic>S. aureus</italic> (approximately 30&#x000a0;%), although the number of isolated anaerobic bacteria was quite low. Polymicrobial infections become more likely with increasing severity and chronicity of the diabetic foot ulcer [<xref ref-type="bibr" rid="CR40">40</xref>], and these occurred in more than half of our patients. Bacteriological eradication was high in both treatment groups; somewhat higher eradication was seen for MXF versus PIP/TAZ&#x02013;AMC in polymicrobial infections (76.8 versus 69.8&#x000a0;%). Several previous studies reported higher levels of MRSA infection (30&#x02013;50&#x000a0;%) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] than those seen in the RELIEF study (6&#x02013;7&#x000a0;%). However, the vast majority of the DFIs treated in this study were community-acquired infections, while in most European countries MRSA infections tend to occur more commonly in patients who have been in hospital; moreover, regional differences in MRSA prevalence might also play a role. Nevertheless, MRSA infections are not necessarily more severe than MSSA infections [<xref ref-type="bibr" rid="CR43">43</xref>]. In this study, MRSA might have been present simply as a colonizer, particularly in the patients in whom MRSA was isolated but who experienced a clinical cure without a specific anti-MRSA agent (notably when there was a low or a lack of susceptibility of MRSA to either MXF or PIP/TAZ&#x02013;AMC).</p><p>Both treatments were well tolerated with similar percentages of patients experiencing any adverse events or drug-related serious adverse events at low frequencies. None of the deaths reported in this clinical trial was drug-related.</p><p>Gyssens et al. [<xref ref-type="bibr" rid="CR22">22</xref>] provide an extensive commentary on the strengths and weaknesses of the RELIEF study design, of which the pre-randomization stratification is identified as a key strength and a feature which has not, to date, been included in the design of other skin and soft tissue infection clinical trials. The strict methodology used in the RELIEF study provided an in-depth and accurate assessment of patients and disease characteristics and assessment by a blinded DRC, prospective use of the Wilson Risk Class, and standardized photo assessment of lesions all helped to remove investigator bias [<xref ref-type="bibr" rid="CR22">22</xref>]. We acknowledge that subgroup analysis is associated with limitations; in particular, the relatively low number of patients with diabetic foot infections in each treatment arm results in an insufficient statistical power and limits the interpretation of the results of this study to the patient population with DFI in general. Therefore, these results should be interpreted cautiously.</p><p>In conclusion, IV/PO MXF monotherapy is clinically and bacteriologically similar to PIP/TAZ&#x02013;AMC in DFI and is an effective and valuable treatment option for patients with moderate to severe DFI. Moxifloxacin treatment was well tolerated; therefore, in combination with surgery, sequential MXF monotherapy is an appropriate treatment choice for DFI patients with a range of severities, particularly for those with polymicrobial infections. Although infection was cured in the majority of patients, many patients underwent surgery and/or an (initial) amputation, highlighting the importance of early recognition and subsequent prompt treatment of DFIs.</p></sec></body><back><ack><p>The authors are grateful to all the investigators and study centers who participated in the RELIEF study. <italic>Belgium</italic>: Dr. D. Ballaux, Antwerp; Prof. F. Jacobs, Brussels; Dr. K. Spincemaille, Brussels; Dr. K. Van Acker, Bornem/Antwerp; <italic>Bulgaria</italic>: Assoc. Prof. M. Kadurina, Sofia; Dr. G. Lefterov, Ruse; <italic>Germany</italic>: Prof. P. Altmeyer, Bochum; Prof. H. Gollnick, Magdeburg; Prof. C. Sunderk&#x000f6;tter, M&#x000fc;nster; Prof. M. Winkler, Hannover; <italic>Greece</italic>: Prof. A. Skoutelis, Athens; <italic>Hungary</italic>: Prof. &#x000c1;. Altorjay, Sz&#x000e9;kesfeh&#x000e9;rv&#x000e1;r; Dr. L. Damjanovich, Debrecen; Dr. F. Halmos, Kaposv&#x000e1;r; Dr. E. Kisida, Budapest; Prof. A. Nagy, Veszpr&#x000e9;m; Prof. A. Ol&#x000e1;h, Gy&#x00151;r; <italic>Israel</italic>: Dr. G. Rahav, Tel Hashomer; Prof. I. Potasman, Haifa; Prof. R. Raz, Afula; <italic>Latvia</italic>: Dr. M. Aizsilniece, Riga; D. Krievins, Riga; U. Kupcs, Valmiera; V. Rozitis, Liep&#x00101;ja; Dr. I. Satilovs, Daugavpils; <italic>Lithuania</italic>: S. Ausra, &#x00160;iauliai; A. Gradauskas, Vilnius; E. Varanauskiene, Kaunas; <italic>Poland</italic>: Prof. W. Karnafel, Warsaw; Dr. M. Melaniuk, Lublin; Dr. A. Wolski, Lublin; <italic>Romania</italic>: Prof. R.M. Cosgarea, Cluj-Napoca; Prof. M. Graur, Ia&#x0015f;i; Dr. S.C. Tivadar, Bucharest; Assoc. Prof. I.A. Veresiu, Cluj-Napoca; <italic>Russia</italic>: Prof. I. Gurieva, Moscow; Prof. A. Severtsev, Moscow; Prof. N. Vorochobina, St. Petersburg; Prof. V. Yakusevich, Yaroslavl; Prof. A. Zouzova, Smolensk; <italic>South Africa</italic>: Dr. M.M. De Vries Basson, Bellville; Dr. L. Van Zyl, Worcester; Dr. N.C. Wright, Johannesburg; <italic>Spain</italic>: Prof. J.M. Tellado, Madrid; <italic>Ukraine</italic>: O. Dziublyk, Kiev; I. Herych, Lviv; A. Lissov, Kiev; V. Mishalov, Kiev; O. Pyptiuk, Ivano-Frankivsk; A. Zaychuk, Odessa; <italic>United Kingdom</italic>: Prof. S. MacRury, Inverness. Highfield Communication, Oxford, UK (funded by Bayer HealthCare) provided editorial assistance in the preparation of this manuscript. This study was funded and supported by Bayer Healthcare.</p><sec id="d29e2817"><title>Conflict of interest</title><p>N.C.S. has received research grants from GlaxoSmithKline, NovoNordisk, Sanofi Aventis, Pfizer, LifeScan, and Ferring, and consultancy fees from DSM Pharmaceuticals and Pfizer. M.D. has received research grants from Pfizer and Bayer, and honoraria from Pfizer, Bayer, Novartis, and Johnson &#x00026; Johnson. P.K. has received honoraria (lecture fees) from Janssen Cilag, Bayer, Novartis, and Pfizer. I.C.G. has a research relationship with Astra-Zeneca and Cubist, has received research grants from MSD and Bayer, honoraria from Pfizer, consultancy fees from ECDC, and royalties from Reed Business. D.N. has received fees for attending advisory boards or given lectures for symposia supported by Astra-Zeneca, Astellas, Pfizer, Johnson &#x00026; Johnson, and Bayer, has received research grants from Bayer and Pfizer, and has received no fees in relation to this manuscript. P.R. and P.A. are employees of Bayer HealthCare. J.A. is an employee and stockholder of Bayer HealthCare.</p></sec><sec id="d29e2822"><title>Ethical standard</title><p>All patients provided written informed consent. Ethical committees at all participating centers have given documented approval of the study. The study was carried out according to the Declaration of Helsinki and Good Clinical Practice guidelines.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>WS</given-names></name><name><surname>Lipsky</surname><given-names>BA</given-names></name></person-group><article-title>Medical therapy of diabetic foot infections</article-title><source>J Am Podiatr Med Assoc</source><year>2010</year><volume>100</volume><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">20847353</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>SB</given-names></name></person-group><article-title>Management of diabetic foot infections in an era of increasing microbial resistance</article-title><source>Curr Infect Dis Rep</source><year>2009</year><volume>11</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1007/s11908-009-0053-z</pub-id><pub-id pub-id-type="pmid">19698281</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolau</surname><given-names>DP</given-names></name><name><surname>Stein</surname><given-names>GE</given-names></name></person-group><article-title>Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics</article-title><source>J Am Podiatr Assoc</source><year>2010</year><volume>100</volume><fpage>52</fpage><lpage>63</lpage></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavery</surname><given-names>LA</given-names></name><name><surname>Armstrong</surname><given-names>DG</given-names></name><name><surname>Wunderlich</surname><given-names>RP</given-names></name><name><surname>Mohler</surname><given-names>MJ</given-names></name><name><surname>Wendel</surname><given-names>CS</given-names></name><name><surname>Lipsky</surname><given-names>BA</given-names></name></person-group><article-title>Risk factors for foot infections in individuals with diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1288</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.2337/dc05-2425</pub-id><pub-id pub-id-type="pmid">16732010</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tentolouris</surname><given-names>N</given-names></name><name><surname>Al-Sabbagh</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>MG</given-names></name><name><surname>Boulton</surname><given-names>AJM</given-names></name><name><surname>Jude</surname><given-names>EB</given-names></name></person-group><article-title>Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a 5-year follow-up study</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1598</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.7.1598</pub-id><pub-id pub-id-type="pmid">15220234</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanolkar</surname><given-names>MP</given-names></name><name><surname>Bain</surname><given-names>SC</given-names></name><name><surname>Stephens</surname><given-names>JW</given-names></name></person-group><article-title>The diabetic foot</article-title><source>QJM</source><year>2008</year><volume>101</volume><fpage>685</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hcn027</pub-id><pub-id pub-id-type="pmid">18353793</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prompers</surname><given-names>L</given-names></name><name><surname>Huijberts</surname><given-names>M</given-names></name><name><surname>Apelqvist</surname><given-names>J</given-names></name><etal/></person-group><article-title>High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale Study</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0491-1</pub-id><pub-id pub-id-type="pmid">17093942</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClaine</surname><given-names>RJ</given-names></name><name><surname>Husted</surname><given-names>TL</given-names></name><name><surname>Hebbeler-Clark</surname><given-names>RS</given-names></name><name><surname>Solomkin</surname><given-names>JS</given-names></name></person-group><article-title>Meta-analysis of trials evaluating parenteral antimicrobial therapy for skin and soft tissue infections</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1086/651264</pub-id><pub-id pub-id-type="pmid">20210644</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citron</surname><given-names>DM</given-names></name><name><surname>Goldstein</surname><given-names>EJC</given-names></name><name><surname>Merriam</surname><given-names>CV</given-names></name><name><surname>Lipsky</surname><given-names>BA</given-names></name><name><surname>Abramson</surname><given-names>MA</given-names></name></person-group><article-title>Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents</article-title><source>J Clin Microbiol</source><year>2007</year><volume>45</volume><fpage>2819</fpage><lpage>2828</lpage><pub-id pub-id-type="doi">10.1128/JCM.00551-07</pub-id><pub-id pub-id-type="pmid">17609322</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>FW</given-names><suffix>Jr</suffix></name></person-group><article-title>The dysvascular foot: a system for diagnosis and treatment</article-title><source>Foot Ankle</source><year>1981</year><volume>2</volume><fpage>64</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">7319435</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavery</surname><given-names>LA</given-names></name><name><surname>Armstrong</surname><given-names>DG</given-names></name><name><surname>Harkless</surname><given-names>LB</given-names></name></person-group><article-title>Classification of diabetic foot wounds</article-title><source>J Foot Ankle Surg</source><year>1996</year><volume>35</volume><fpage>528</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/S1067-2516(96)80125-6</pub-id><pub-id pub-id-type="pmid">8986890</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>DG</given-names></name><name><surname>Lavery</surname><given-names>LA</given-names></name><name><surname>Harkless</surname><given-names>LB</given-names></name></person-group><article-title>Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>855</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.2337/diacare.21.5.855</pub-id><pub-id pub-id-type="pmid">9589255</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaper</surname><given-names>NC</given-names></name></person-group><article-title>Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies</article-title><source>Diabetes Metab Res Rev</source><year>2004</year><volume>20</volume><issue>Suppl 1</issue><fpage>S90</fpage><lpage>S95</lpage><pub-id pub-id-type="doi">10.1002/dmrr.464</pub-id><pub-id pub-id-type="pmid">15150820</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsky</surname><given-names>BA</given-names></name><name><surname>Berendt</surname><given-names>AR</given-names></name><name><surname>Deery</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of diabetic foot infections</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>885</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1086/424846</pub-id><pub-id pub-id-type="pmid">15472838</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavery</surname><given-names>LA</given-names></name><name><surname>Armstrong</surname><given-names>DG</given-names></name><name><surname>Murdoch</surname><given-names>DP</given-names></name><name><surname>Peters</surname><given-names>EJ</given-names></name><name><surname>Lipsky</surname><given-names>BA</given-names></name></person-group><article-title>Validation of the Infectious Diseases Society of America&#x02019;s diabetic foot infection classification system</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><fpage>562</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1086/511036</pub-id><pub-id pub-id-type="pmid">17243061</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmiston</surname><given-names>CE</given-names></name><name><surname>Krepel</surname><given-names>CJ</given-names></name><name><surname>Seabrook</surname><given-names>GR</given-names></name><etal/></person-group><article-title>In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><fpage>1012</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.3.1012-1016.2004</pub-id><pub-id pub-id-type="pmid">14982797</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stass</surname><given-names>H</given-names></name><name><surname>Kubitza</surname><given-names>D</given-names></name></person-group><article-title>Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man</article-title><source>J Antimicrob Chemother</source><year>1999</year><volume>43(Suppl B)</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/jac/43.suppl_2.83</pub-id><pub-id pub-id-type="pmid">10382880</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name><name><surname>Stass</surname><given-names>H</given-names></name><name><surname>Brunner</surname><given-names>M</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>JG</given-names></name><name><surname>Lackner</surname><given-names>E</given-names></name><name><surname>Eichler</surname><given-names>HG</given-names></name></person-group><article-title>Penetration of moxifloxacin into peripheral compartments in humans</article-title><source>Antimicrob Agents Chemother</source><year>1999</year><volume>43</volume><fpage>2345</fpage><lpage>2349</lpage><pub-id pub-id-type="pmid">10508004</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majcher-Peszynska</surname><given-names>J</given-names></name><name><surname>Sass</surname><given-names>M</given-names></name><name><surname>Schipper</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort</article-title><source>Eur J Clin Pharmacol</source><year>2011</year><volume>67</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1007/s00228-010-0903-5</pub-id><pub-id pub-id-type="pmid">20871984</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wise</surname><given-names>R</given-names></name><name><surname>Andrews</surname><given-names>JM</given-names></name><name><surname>Marshall</surname><given-names>G</given-names></name><name><surname>Hartman</surname><given-names>G</given-names></name></person-group><article-title>Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration</article-title><source>Antimicrob Agents Chemother</source><year>1999</year><volume>43</volume><fpage>1508</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">10348784</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsky</surname><given-names>BA</given-names></name><name><surname>Giordano</surname><given-names>P</given-names></name><name><surname>Choudhri</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><article-title>Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin&#x02013;tazobactam/amoxicillin&#x02013;clavulanate</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>60</volume><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm130</pub-id><pub-id pub-id-type="pmid">17553812</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyssens</surname><given-names>IC</given-names></name><name><surname>Dryden</surname><given-names>M</given-names></name><name><surname>Kujath</surname><given-names>P</given-names></name><etal/></person-group><article-title>A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections</article-title><source>J Antimicrob Chemother</source><year>2011</year><volume>66</volume><fpage>2632</fpage><lpage>2642</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr344</pub-id><pub-id pub-id-type="pmid">21896561</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsky</surname><given-names>BA</given-names></name><name><surname>Armstrong</surname><given-names>DG</given-names></name><name><surname>Citron</surname><given-names>DM</given-names></name><name><surname>Tice</surname><given-names>AD</given-names></name><name><surname>Morgenstern</surname><given-names>DE</given-names></name><name><surname>Abramson</surname><given-names>MA</given-names></name></person-group><article-title>Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1695</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67694-5</pub-id><pub-id pub-id-type="pmid">16291062</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SE</given-names></name><name><surname>Solomkin</surname><given-names>JS</given-names></name><name><surname>Le</surname><given-names>V</given-names></name><name><surname>Cammarata</surname><given-names>SK</given-names></name><name><surname>Bruss</surname><given-names>JB</given-names></name></person-group><article-title>A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid</article-title><source>Am J Surg</source><year>2003</year><volume>185</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/S0002-9610(02)01411-3</pub-id><pub-id pub-id-type="pmid">12657392</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Schaper N, Dryden M, Kujath P et al. Efficacy of moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study (abstract). Presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, 10&#x02013;13 April 2010, P1550.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzun</surname><given-names>G</given-names></name><name><surname>Solmazgul</surname><given-names>E</given-names></name><name><surname>Curuksulu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Procalcitonin as a diagnostic aid in diabetic foot infections</article-title><source>Tohoku J Exp Med</source><year>2007</year><volume>213</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1620/tjem.213.305</pub-id><pub-id pub-id-type="pmid">18075234</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nather</surname><given-names>A</given-names></name><name><surname>Chionh</surname><given-names>SB</given-names></name><name><surname>Han</surname><given-names>AY</given-names></name><name><surname>Chan</surname><given-names>PP</given-names></name><name><surname>Nambiar</surname><given-names>A</given-names></name></person-group><article-title>Effectiveness of vacuum-assisted closure (VAC) therapy in the healing of chronic diabetic foot ulcers</article-title><source>Ann Acad Med Singapore</source><year>2010</year><volume>39</volume><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">20535423</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>DR</given-names></name><name><surname>Talan</surname><given-names>DA</given-names></name><name><surname>Nichols</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Once-daily, high-dose levofloxacin versus ticarcillin&#x02013;clavulanate alone or followed by amoxicillin&#x02013;clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial</article-title><source>Clin Infect Dis</source><year>2002</year><volume>35</volume><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1086/341026</pub-id><pub-id pub-id-type="pmid">12145720</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipsky</surname><given-names>BA</given-names></name><name><surname>Itani</surname><given-names>K</given-names></name><name><surname>Norden</surname><given-names>C</given-names></name><collab>Linezolid Diabetic Foot Infections Study Group</collab></person-group><article-title>Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin&#x02013;sulbactam/amoxicillin&#x02013;clavulanate</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1086/380449</pub-id><pub-id pub-id-type="pmid">14679443</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giordano</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Pertel</surname><given-names>P</given-names></name><name><surname>Herrington</surname><given-names>J</given-names></name><name><surname>Kowalsky</surname><given-names>S</given-names></name></person-group><article-title>Sequential intravenous/oral moxifloxacin versus intravenous piperacillin&#x02013;tazobactam followed by oral amoxicillin&#x02013;clavulanate for the treatment of complicated skin and skin structure infection</article-title><source>Int J Antimicrob Agents</source><year>2005</year><volume>26</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2005.07.017</pub-id><pub-id pub-id-type="pmid">16229991</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noel</surname><given-names>GJ</given-names></name><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Bagchi</surname><given-names>P</given-names></name><name><surname>Ianus</surname><given-names>J</given-names></name><name><surname>Strauss</surname><given-names>RS</given-names></name></person-group><article-title>A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><fpage>647</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1086/526527</pub-id><pub-id pub-id-type="pmid">18225981</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crouzet</surname><given-names>J</given-names></name><name><surname>Lavigne</surname><given-names>JP</given-names></name><name><surname>Richard</surname><given-names>JL</given-names></name><name><surname>Sotto</surname><given-names>A</given-names></name><collab>N&#x000ee;mes University Hospital Working Group on the Diabetic Foot (GP30)</collab></person-group><article-title>Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy</article-title><source>Int J Infect Dis</source><year>2011</year><volume>15</volume><fpage>e601</fpage><lpage>e610</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2011.05.003</pub-id><pub-id pub-id-type="pmid">21737333</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harkless</surname><given-names>L</given-names></name><name><surname>Boghossian</surname><given-names>J</given-names></name><name><surname>Pollak</surname><given-names>R</given-names></name><etal/></person-group><article-title>An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers</article-title><source>Surg Infect (Larchmt)</source><year>2005</year><volume>6</volume><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1089/sur.2005.6.27</pub-id><pub-id pub-id-type="pmid">15865549</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymakers</surname><given-names>JT</given-names></name><name><surname>Houben</surname><given-names>AJ</given-names></name><name><surname>van der Heyden</surname><given-names>JJ</given-names></name><name><surname>Tordoir</surname><given-names>JH</given-names></name><name><surname>Kitslaar</surname><given-names>PJ</given-names></name><name><surname>Schaper</surname><given-names>NC</given-names></name></person-group><article-title>The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb</article-title><source>Diabet Med</source><year>2001</year><volume>18</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1046/j.1464-5491.2001.00460.x</pub-id><pub-id pub-id-type="pmid">11318845</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prompers</surname><given-names>L</given-names></name><name><surname>Schaper</surname><given-names>N</given-names></name><name><surname>Apelqvist</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study</article-title><source>Diabetologia</source><year>2008</year><volume>51</volume><fpage>747</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1007/s00125-008-0940-0</pub-id><pub-id pub-id-type="pmid">18297261</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschl</surname><given-names>M</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><name><surname>Hirschl</surname><given-names>AM</given-names></name><name><surname>Georgopoulos</surname><given-names>A</given-names></name></person-group><article-title>Effects of macro- and microcirculatory functions on ceftriaxone concentrations in tissues of patients with stage IV peripheral arterial occlusive disease</article-title><source>Antimicrob Agents Chemother</source><year>1995</year><volume>39</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1128/AAC.39.1.15</pub-id><pub-id pub-id-type="pmid">7695297</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>GE</given-names></name><name><surname>Schooley</surname><given-names>S</given-names></name><name><surname>Peloquin</surname><given-names>CA</given-names></name><name><surname>Missavage</surname><given-names>A</given-names></name><name><surname>Havlichek</surname><given-names>DH</given-names></name></person-group><article-title>Linezolid tissue penetration and serum activity against strains of methicillin-resistant <italic>Staphylococcus aureus</italic> with reduced vancomycin susceptibility in diabetic patients with foot infections</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>60</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1093/jac/dkm271</pub-id><pub-id pub-id-type="pmid">17673476</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zammit</surname><given-names>MC</given-names></name><name><surname>Fiorentino</surname><given-names>L</given-names></name><name><surname>Cassar</surname><given-names>K</given-names></name><name><surname>Azzopardi</surname><given-names>LM</given-names></name><name><surname>LaFerla</surname><given-names>G</given-names></name></person-group><article-title>Factors affecting gentamicin penetration in lower extremity ischemic tissues with ulcers</article-title><source>Int J Low Extrem Wounds</source><year>2011</year><volume>10</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1177/1534734611418571</pub-id><pub-id pub-id-type="pmid">21856974</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vick-Fragoso</surname><given-names>R</given-names></name><name><surname>Hern&#x000e1;ndez-Oliva</surname><given-names>G</given-names></name><name><surname>Cruz-Alc&#x000e1;zar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections</article-title><source>Infection</source><year>2009</year><volume>37</volume><fpage>407</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1007/s15010-009-8468-x</pub-id><pub-id pub-id-type="pmid">19768381</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>PC</given-names></name><name><surname>Berendt</surname><given-names>AR</given-names></name><name><surname>Lipsky</surname><given-names>BA</given-names></name></person-group><article-title>Clinical management of diabetic foot infection: diagnostics, therapeutics and the future</article-title><source>Expert Rev Anti Infect Ther</source><year>2007</year><volume>5</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1586/14787210.5.1.117</pub-id><pub-id pub-id-type="pmid">17266459</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>CN</given-names></name><name><surname>Prasad</surname><given-names>YD</given-names></name><name><surname>Boulton</surname><given-names>AJ</given-names></name><name><surname>Jude</surname><given-names>EB</given-names></name></person-group><article-title>Methicillin-resistant <italic>Staphylococcus aureus</italic> in the diabetic foot clinic: a worsening problem</article-title><source>Diabet Med</source><year>2003</year><volume>20</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1046/j.1464-5491.2003.00860.x</pub-id><pub-id pub-id-type="pmid">12581269</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecornet</surname><given-names>E</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name><name><surname>Jacqueminet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Preemptive isolation to prevent methicillin-resistant <italic>Staphylococcus aureus</italic> cross-transmission in diabetic foot</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>2341</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.2337/dc07-0743</pub-id><pub-id pub-id-type="pmid">17586742</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmonds</surname><given-names>M</given-names></name></person-group><article-title>The treatment of diabetic foot infections: focus on ertapenem</article-title><source>Vasc Health Risk Manage</source><year>2009</year><volume>5</volume><fpage>949</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.2147/VHRM.S3162</pub-id></mixed-citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>ABI</term><def><p>Ankle&#x02013;brachial index</p></def></def-item><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>AMC</term><def><p>Amoxicillin/clavulanic acid</p></def></def-item><def-item><term>b.d.</term><def><p><italic>Bis die</italic>, twice daily</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>cSSSI</term><def><p>Complicated skin and skin structure infection</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>DFI</term><def><p>Diabetic foot infection</p></def></def-item><def-item><term>DRC</term><def><p>Data Review Committee</p></def></def-item><def-item><term>ECCMID</term><def><p>European Congress of Clinical Microbiology and Infectious Diseases</p></def></def-item><def-item><term>EOT</term><def><p>End of treatment</p></def></def-item><def-item><term>HbA<sub>1c</sub></term><def><p>Glycosylated hemoglobin</p></def></def-item><def-item><term>ITT</term><def><p>Intent-to-treat</p></def></def-item><def-item><term>IV</term><def><p>Intravenous</p></def></def-item><def-item><term>MBV</term><def><p>Microbiologically valid</p></def></def-item><def-item><term>MRSA</term><def><p>Methicillin-resistant <italic>Staphylococcus aureus</italic></p></def></def-item><def-item><term>MXF</term><def><p>Moxifloxacin</p></def></def-item><def-item><term>PCT</term><def><p>Procalcitonin</p></def></def-item><def-item><term>PEDIS</term><def><p>Perfusion, extent/size, depth/tissue loss, infection, and sensation</p></def></def-item><def-item><term>PIP/TAZ</term><def><p>Piperacillin/tazobactam</p></def></def-item><def-item><term>PP</term><def><p>Per-protocol</p></def></def-item><def-item><term>PO</term><def><p><italic>Per os</italic>, orally</p></def></def-item><def-item><term>q.d.</term><def><p><italic>Quaque die</italic>, once daily</p></def></def-item><def-item><term>t.d.s.</term><def><p><italic>Ter die sumendum</italic>, three times daily</p></def></def-item><def-item><term>TOC</term><def><p>Test-of-cure</p></def></def-item></def-list></def-list></glossary></back></article>